John Peter Gutfreund - Aug 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role: Director
Signature: /s/ John Peter Gutfreund
Stock symbol: OCX
Transactions as of: Aug 15, 2022
Transactions value $: $23,250
Form type: 4
Date filed: 8/17/2022, 08:19 PM
Previous filing: Aug 8, 2022
Next filing: Dec 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCX	Common Stock, no par value	Award	$0	+10K		$0.00	10K	Aug 15, 2022	Direct	F1
transaction	OCX	Common Stock, no par value	Purchase	$23.3K	+25K		$0.93	25K	Aug 15, 2022	See footnote	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Award	$0	+45K		$0.00	45K	Aug 15, 2022	Common Stock	45K	$0.97	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2	The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities.
F4	Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.